A PYMNTS Company

FTC OKs Hikma Pharma Acquisition With Conditions

By  |  April 19, 2022

Generic drug maker Hikma Pharmaceuticals  has won US antitrust approval to buy Custopharm, Inc on condition that it divest an injectable steroid, the US Federal Trade Commission said on Tuesday.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Hikma, which makes anesthetics, pain medications, sedatives, neuromuscular agents and other drugs, announced the deal in September as a way for it to strengthen its injectable treatments unit in the United States. It was valued at $425 million at that time. read more

    Under a deal struck with the FTC, Custopharm’s parent company will retain assets related to the corticosteroid drug triamcinolone acetonide, or TCA, by shifting it to another subsidiary.

    “Hikma’s acquisition of Custopharm’s TCA business could have caused significant harm for patients who use TCA to treat severe skin conditions, allergies, and inflammation,” Holly Vedova, director of the FTC’s Bureau of Competition, said in a statement.

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.